Takeda announced the completion of the 7-year pivotal Phase III Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluating its dengue vaccine, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated])… read more.
The Dengue vaccine has an efficacy rate of over 50% in reducing disease cases, with lasting effects and a very good safety profile. This is confirmed by the first global meta-analysis on the efficacy of TAK-003, better… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
